Meds & supplements › Etelcalcetide
Medicine
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Storage
Store in the original carton in refrigerator at 2°C to 8°C (36°F to 46°F) to protect from light. Once removed from the refrigerator:
sofidex [Internet]. Daloreum; c2026. Etelcalcetide; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/etelcalcetide
sofidex. (2026, August 2). Etelcalcetide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/etelcalcetide
Etelcalcetide. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/etelcalcetide
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.